S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
S&P 500   4,071.70 (-0.12%)
DOW   34,429.88 (+0.10%)
QQQ   292.55 (-0.40%)
AAPL   147.81 (-0.34%)
MSFT   255.02 (+0.13%)
META   123.49 (+2.53%)
GOOGL   100.44 (-0.54%)
AMZN   94.13 (-1.43%)
TSLA   194.86 (+0.08%)
NVDA   168.76 (-1.51%)
NIO   13.13 (+8.60%)
BABA   90.06 (+4.79%)
AMD   74.98 (-3.23%)
T   19.02 (-0.89%)
MU   54.68 (-1.46%)
CGC   4.29 (+9.16%)
F   13.86 (-1.56%)
GE   86.88 (+1.90%)
DIS   99.43 (+0.85%)
AMC   8.17 (+0.00%)
PYPL   74.66 (-4.93%)
PFE   50.91 (-0.33%)
NFLX   320.41 (+1.09%)
TSE:IN

InMed Pharmaceuticals - IN Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
C$4.19
▼
C$4.19
52-Week Range
N/A
Volume
17,035 shs
Average Volume
29,552 shs
Market Capitalization
C$33.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IN stock logo

About InMed Pharmaceuticals (TSE:IN) Stock

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IN Stock News Headlines

November 23, 2022 | msn.com
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
November 17, 2022 | finance.yahoo.com
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
November 16, 2022 | msn.com
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
November 16, 2022 | benzinga.com
Thinking about buying stock in Fast Radius, Camber Energy, InMed Pharmaceuticals, Taiwan Semiconductor, or Exela Technologies?
November 16, 2022 | msn.com
InMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson's
November 12, 2022 | finanznachrichten.de
InMed Pharmaceuticals Inc.: InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
November 12, 2022 | benzinga.com
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
September 30, 2022 | marketwatch.com
InMed Pharmaceuticals Shares Rise 30% on Higher-Than-Normal Volume
September 9, 2022 | nasdaq.com
InMed Pharma Gains 9%
August 25, 2022 | marketwatch.com
InMed Pharma to Consolidate Shares
August 25, 2022 | uk.investing.com
Here's Why InMed Pharmaceuticals Shares Are Getting Hammered Today
August 25, 2022 | seekingalpha.com
InMed Pharmaceuticals sinks 16% over consolidating 1 for 25 shares to meet listing requirements
July 25, 2022 | finance.yahoo.com
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
July 18, 2022 | markets.businessinsider.com
InMed Pharma Names Michael Woudenberg As COO
June 14, 2022 | finance.yahoo.com
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
June 9, 2022 | finance.yahoo.com
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
May 4, 2022 | finanznachrichten.de
Edison Investment Research Limited: InMed Pharmaceuticals : Notable Launches of High-Value Rare Cannabinoids
April 21, 2022 | baystreet.ca
This is Why Investors Are Excited About the Potential of Rare Cannabinoids
March 17, 2022 | benzinga.com
InMed Launching Additional Rare Cannabinoids In Response To Demand
March 17, 2022 | seekingalpha.com
InMed CFO steps down, interim CFO appointed
March 17, 2022 | nasdaq.com
InMed Pharma CFO Bruce Colwill To Retire - Quick Facts
March 17, 2022 | finance.yahoo.com
InMed Announces Management Changes
March 4, 2022 | benzinga.com
InMed Pharmaceuticals Expanding Portfolio In Rare Cannabinoid Market
February 17, 2022 | benzinga.com
InMed's Evolution To Commercial Sales Featured In Research Report
February 16, 2022 | finanznachrichten.de
Edison Investment Research Limited: InMed Pharmaceuticals (INM): Generating Commercial Sales of CBC and CBT
See More Headlines

Receive IN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:IN
CUSIP
N/A
CIK
N/A
Web
www.inmedpharma.com
Phone
604-669-7207
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
8.48
Current Ratio
2.13
Quick Ratio
1.45

Sales & Book Value

Annual Sales
C$574,677.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
10.40
Book Value
C$0.76 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
8,051,000
Free Float
N/A
Market Cap
C$33.73 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Eric A. Adams (Age 58)
    Pres, CEO & Director
    Comp: $488.44k
  • Ms. Alexandra Diane-Janet Mancini (Age 69)
    Sr. VP of Clinical & Regulatory Affairs
    Comp: $337.13k
  • Dr. Sazzad Hossain M.Sc. (Age 64)
    Ph.D., Co-Founder
  • Ms. Brenda Edwards C.M.A.
    CPA, Interim Chief Financial Officer
  • Mr. Michael Woudenberg P.Eng. (Age 55)
    Chief Operating Officer
  • Colin Clancy
    Sr. Director of Investor Relations
  • Mr. Jerry P. Griffin
    VP of Sales & Marketing
  • Dr. Eric Chih-Hsien Hsu (Age 52)
    Sr. VP of Preclinical R&D
  • Dr. Shane A. Johnson Ph.D.
    Sr. VP & GM of BayMedica
  • Dr. Ado Muhammad
    Sr. Consultant of Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IN Stock - Frequently Asked Questions

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMed Pharmaceuticals investors own include OrganiGram (OGI), Aurora Cannabis (ACB), Canopy Growth (WEED), Baidu (BIDU), Cara Therapeutics (CARA), Copper Mountain Mining (CMMC), Corbus Pharmaceuticals (CRBP), HEXO (HEXO), InMed Pharmaceuticals (IMLFF) and Immunomedics (IMMU).

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IN."

How do I buy shares of InMed Pharmaceuticals?

Shares of IN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does InMed Pharmaceuticals make?

InMed Pharmaceuticals (TSE:IN) has a market capitalization of C$0.00 and generates C$574,677.00 in revenue each year.

How can I contact InMed Pharmaceuticals?

The official website for the company is www.inmedpharma.com. The company can be reached via phone at 604-669-7207.

This page (TSE:IN) was last updated on 12/2/2022 by MarketBeat.com Staff